Jones Lang LaSalle
Orchid Cellmark Names New Chief
Orchid Cellmark (Nasdaq: Orch) today said it appointed Thomas A. Bologna, 57, as CEO, replacing Dr. Paul Kelly, who has left the company.
Bologna will also serve as a director of Princeton-based Orchid Cellmark. Bologna previously headed Quorex Pharmaceuticals, a company focused on pre-clinical anti-infective treatments.
The executive holds B.S. and M.B.A. degrees from New York University. Orchid Cellmark provides human DNA-testing services for forensic, family relationship and security applications; and agricultural DNA testing for selective trait breeding.
Orchid stock changed hands at $6.74, up $0.58, this afternoon. - Martin C. Daks
Orchid Cellmark Names New Chief
Orchid Cellmark (Nasdaq: Orch) today said it appointed Thomas A. Bologna, 57, as CEO, replacing Dr. Paul Kelly, who has left the company.
Bologna will also serve as a director of Princeton-based Orchid Cellmark. Bologna previously headed Quorex Pharmaceuticals, a company focused on pre-clinical anti-infective treatments.
The executive holds B.S. and M.B.A. degrees from New York University. Orchid Cellmark provides human DNA-testing services for forensic, family relationship and security applications; and agricultural DNA testing for selective trait breeding.
Orchid stock changed hands at $6.74, up $0.58, this afternoon. - Martin C. Daks
posted by Jones Lang LaSalle NJ News Blog at 10:23 AM
<< Home